Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...
Novo Nordisk 's ( NVO 3.84%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance ...
Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results